Addiction Solution Source

A six-year legal battle against Pfizer Inc just made whistleblower John Kopchinski a rich man. Taking on a corporate giant such as Pfizer can be overwhelming, but Kopchinski was motivated by wanting the truth to be told.

The Gulf War veteran and former Pfizer sales representative will earn more than $51.5 million as a result of his whistleblower lawsuit against the world’s biggest drugmaker and the record penalty the company must pay the U.S. government for its massive marketing transgressions.

Kopchinski was appalled by Pfizer’s tactics in selling the pain drug Bextra and filed a “qui tam” lawsuit in 2003, sparking federal and state probes. The company is paying $2.3 billion in civil and criminal penalties and is pleading guilty to a felony charge for promoting Bextra and 12 other drugs for unapproved uses and doses.

Kopchinski was fired by Pfizer in 2003 when he wouldn’t promote drugs to increase the company’s profits. This was two years before the company had to pull Bextra from the market over concerns that it raised the risk of heart attacks and strokes.

Dr. Charles Gant’s new book has just been released. I have read it and it is excellent.

Order now at Amazon:
End Your Addiction Now: A Proven Nutritional Supplement Program That Can Set You Free

Here is the write up from the publisher about the book:

Whether it is to alcohol, drugs, smoking, or food, addiction is an overwhelming and destructive force that negatively impacts the lives of those in its grip. While there are programs galore that promise an end to these dependencies, the truth is, far too many “reformed” addicts fall right back into their old habits.

Why?

Because powerful biochemical factors override the psychological will to quit. End Your Addiction Now is a unique book that not only explores the real cause of this recurring problem, but also offers a proven biochemical approach that can break addiction once and for all.

Written in easy-to-understand language, End Your Addiction Now is based upon the extensive research and medical practice of Dr. Charles Gant and other pioneers in the field of orthomolecular medicine. It both guides readers to physicians and facilities that support a biochemical approach to the treatment of substance-use disorders, and provides step-by-step directions for those who want to quit their addictions on their own.

Researchers from the Stanford University School of Medicine think it’s high time that prescription drug labeling tell you what isn’t known. This sounds like a great new idea!

The researchers want the U.S. Food and Drug Administration to require drug manufacturers to state how new medications compare with similar, existing treatments. In many instance, these statements would indicate that there is no evidence that a new drug is more effective than older ones.

They believe this information would make patients and health-care insurers less likely to pay for newer treatments without evidence that they lead to improved patient outcomes. It would also spur drug and medical-device companies to design more informative clinical trials to test a new product’s superiority over existing therapies.

“Drug and device manufacturers benefit from an unacknowledged information gap that develops as more and more products are tested against a placebo, but not each other.”